Catheter Precision, Inc. is a medical device company bringing solutions to market to improve the treatment of cardiac arrhythmias. The Company is focused on developing technology for electrophysiology (EP) procedures by collaborating with physicians and continuously advancing its products. The Company's two primary products are the View into Ventricular Onset System (VIVO System) and LockeT. The VIVO System is a non-invasive imaging system that offers three-dimensional (3D) cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure. Its product portfolio also includes the Amigo Remote Catheter System. It is developing technology for the treatment of acute decompensated heart failure.
BörsenkürzelVTAK
Name des UnternehmensCatheter Precision Inc
IPO-datumSep 27, 2018
Gegründet am2018
CEOMr. David A. Jenkins
Anzahl der mitarbeiter22
WertpapierartOrdinary Share
GeschäftsjahresendeSep 27
Addresse1670 Highway 160 West
StadtFORT MILL
BörseNYSE American Consolidated
LandUnited States of America
Postleitzahl29708
Telefon19736912000
Websitehttps://www.ramed.com/
BörsenkürzelVTAK
IPO-datumSep 27, 2018
Gegründet am2018
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten